FOXO4-DRI

FOXO4-DRI is a synthetic peptide designed to selectively trigger the death of “senescent” cells, aging cells that have stopped dividing but refuse to die and instead release inflammatory signals into surrounding tissue. It became widely known after a 2017 Cell paper showed it reversed several aging-related markers in mice. It has not been tested in a registered human clinical trial, and no dosage has been established for human use.

Research snapshot

Peptide category	Synthetic D-retro-inverso peptide; senolytic (selectively targets senescent cells)
Primary research interest	Senescent-cell clearance and reversal of aging-related markers
Highest available evidence	Tier 3 — published animal (mouse) research; became widely known after a 2017 Cell paper
Human research available	No — has not entered a registered human clinical trial
Development status	Preclinical, laboratory and animal-stage research compound
Regulatory status	No approved medical use anywhere; sold by research-chemical vendors labeled for research use only, not human use

Technical identity

Primary name	FOXO4-DRI
Alternative names	FOXO4-D-Retro-Inverso peptide
Peptide sequence	Not independently re-verified in this pass — a D-retro-inverso construct built from D-amino acids in reversed sequence order, designed to mimic a region of the FOXO4 transcription factor
Amino-acid length	Not independently re-verified in this pass
Molecular formula	Not independently re-verified in this pass
Molecular weight	Not independently re-verified in this pass
CAS Registry Number	Not independently re-verified in this pass
PubChem CID	Not independently re-verified in this pass
Chemical modifications	D-retro-inverso design (D-amino acids, reversed sequence direction) to resist proteolytic breakdown while retaining the natural sequence’s 3D shape
Peptide class	Senolytic / anti-aging research peptide; interferes with the FOXO4-p53 protein-protein interaction
Primary biological target	FOXO4-p53 interaction within senescent cells, promoting their selective apoptosis
Developer or originator	Academic research group (Baar et al., published in Cell, 2017); not a commercial drug developer
Development status	Preclinical; no confirmed company-led human clinical development program identified

What it is

FOXO4-DRI is a “D-retro-inverso” peptide: a synthetic peptide built from the mirror-image (D-amino acid) versions of the natural L-amino acids, assembled in the opposite sequence direction, so that the resulting molecule presents a similar three-dimensional shape to the natural target sequence while resisting breakdown by the body’s normal protein-digesting enzymes. It was designed to mimic a specific region of FOXO4, a transcription factor (a protein that switches genes on and off) that becomes unusually abundant inside senescent cells.

The peptide was developed by a research group led by Peter de Keizer, then at Erasmus University Medical Center in the Netherlands, and described in a 2017 paper in the journal Cell (Baar et al., “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging”). The paper showed that FOXO4-DRI selectively induced programmed cell death (apoptosis) in senescent cells while sparing healthy, non-senescent cells nearby, and that treating mice with the peptide improved markers of fitness, fur density, and kidney function.

FOXO4-DRI belongs to a broader category of experimental compounds called “senolytics,” substances designed to clear senescent cells, which also includes the drug combination dasatinib plus quercetin and other investigational agents. Unlike some senolytics, FOXO4-DRI has not been pursued in registered human trials as of this review, and it remains a laboratory and animal research compound rather than an approved or clinically tested drug. A company called Cleara Biotech, co-founded by de Keizer, was reported in the years following the 2017 paper to be pursuing senolytic peptide development, though the compound’s clinical development pathway and current status are not clearly documented in public sources reviewed for this entry.

How does it work?

Plain-English explanation

As cells age or become damaged, some of them stop dividing but do not die, a state called senescence. These “zombie cells” build up with age and secrete inflammatory chemicals that can damage nearby healthy tissue, a phenomenon researchers call the senescence-associated secretory phenotype, or SASP. FOXO4-DRI is designed to interfere with a survival signal that helps senescent cells resist dying, which in laboratory studies causes them to finally undergo the programmed cell death they had been evading, while leaving normal, healthy cells alone.

Technical explanation

FOXO4, a forkhead box transcription factor, becomes markedly upregulated in senescent cells and interacts with p53, a tumor-suppressor protein central to apoptosis regulation, keeping it sequestered in the nucleus and preventing it from triggering cell death. FOXO4-DRI is designed to competitively disrupt the FOXO4–p53 protein-protein interaction. This displaces p53, allowing it to relocate to mitochondria and activate the intrinsic (mitochondrial) apoptosis pathway selectively in senescent cells, which are dependent on this survival mechanism, while non-senescent cells, which do not rely on the same FOXO4-mediated survival signal, are reported to be unaffected. The D-retro-inverso design increases resistance to proteolytic (enzymatic protein-breakdown) degradation compared with a natural L-amino-acid peptide of the same sequence, which was intended to improve its stability for in vivo use.

Potential benefits and research applications

Senescent cell clearance (“senolytic” effect)

What is being investigated: whether selectively eliminating senescent cells can improve tissue function and markers of aging. How the effect might occur: by disrupting the FOXO4–p53 interaction that keeps senescent cells alive, triggering apoptosis specifically in that cell population. Evidence: shown in the original 2017 Cell paper in aged and fast-aging (progeroid) mice, where treatment improved fur density, renal function, and overall fitness, and in cell-culture experiments confirming selective apoptosis in senescent versus healthy cells. Strength: animal and laboratory evidence only. Limitation: no human trial has confirmed selective senescent-cell clearance or any clinical benefit in people.

Chemotherapy-related tissue protection

What is being investigated: whether clearing senescent cells generated by chemotoxic drugs could reduce chemotherapy-associated tissue damage or improve recovery. How the effect might occur: chemotherapy drives many cells into senescence; removing those cells may reduce the resulting inflammatory burden. Evidence: reported in mouse models treated with chemotherapy agents in the original and subsequent laboratory studies. Strength: animal/laboratory evidence only. Limitation: not evaluated in human cancer patients, and any interaction with active cancer treatment in humans is unstudied and a mechanism-based safety concern rather than a proven benefit.

Reproductive and endocrine research applications

What is being investigated: effects on age-related decline in testosterone production and spermatogenesis, and on pulmonary fibrosis, based on subsequent animal studies referencing FOXO4-DRI or the FOXO4-p53 disruption strategy. How the effect might occur: through clearance of senescent cells accumulating in testicular or lung tissue with age or fibrotic injury. Evidence: reported in separate rodent studies following the original 2017 publication. Strength: animal/laboratory evidence only, from a smaller and more scattered set of studies than the primary aging literature. Limitation: these are isolated animal findings that have not been replicated in humans or, in most cases, independently confirmed by multiple research groups.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Amounts studied in human research

No established or reliably sourced dosing information was identified. FOXO4-DRI has not been administered to humans in any registered clinical trial identified for this review.

Amounts studied in animal research

In the original 2017 Cell study, mice received FOXO4-DRI by intraperitoneal injection at approximately 10 milligrams per kilogram of body weight, administered on a cyclical schedule (reported as several consecutive daily injections followed by rest periods, repeated over multiple weeks) in both naturally aged mice and a fast-aging progeroid mouse model (evidence category: published animal research). Later animal studies referencing FOXO4-DRI in other disease contexts have used varying doses and schedules; because these studies differ substantially in species, model, and objective, their figures are not interchangeable and should not be read as a single validated animal dosing standard.

Practitioner and community-reported protocols

Peptide-vendor and longevity-community websites describe self-injected protocols for FOXO4-DRI, commonly citing total amounts in the range of roughly 1 to 10 milligrams reconstituted and administered subcutaneously over short cycles (often described as several consecutive days followed by weeks off), loosely modeled on the mouse dosing schedule from the 2017 paper. These figures are widely repeated across peptide-dosing-guide and vendor sites, but the specific human-equivalent conversion is not supported by any published human pharmacokinetic or dosing study, and the original source for any specific human milligram figure could not be verified (evidence category: community/vendor reported; origin unclear). Widely repeated online, but its original source could not be verified. Products described as FOXO4-DRI sold online are typically labeled “research use only,” with no independent verification of purity, concentration, or identity in the material reviewed for this entry.

Side effects, risks, and limitations

No human safety data exists for FOXO4-DRI because it has not been through human clinical trials. In the mouse studies underlying most of the public interest in this peptide, treated animals were not reported to show overt toxicity at the doses and schedules used, but animal tolerability does not establish human safety, and mouse-to-human dose conversion for peptides is not straightforward. Because the compound is designed to trigger apoptosis, a mechanism-based concern is its potential effect on any cell population, healthy or diseased, that depends on similar survival signaling; this has not been systematically studied in humans. As with other unregulated research peptides, material purchased online carries risks around incorrect concentration, contamination, and misidentification that are unrelated to the molecule’s intended biology. Long-term effects of repeated FOXO4-p53 pathway disruption in humans are entirely unknown.

Regulatory and developmental status

FOXO4-DRI has no approved medical use anywhere and has not entered a registered human clinical trial as of this review. It remains a preclinical, laboratory and animal-stage research compound. It is sold by peptide and research-chemical vendors labeled for research use only, not for human use. Public information about any company-led clinical development program for this peptide or a related senolytic candidate is limited and could not be independently confirmed to have reached human testing.

Frequently asked questions

What is FOXO4-DRI?

FOXO4-DRI is a synthetic, mirror-image (“D-retro-inverso”) peptide designed to selectively kill senescent, or “zombie,” cells by disrupting a survival signal they depend on. It was described in a 2017 Cell paper that showed benefits in aged mice.

How does FOXO4-DRI work?

It blocks the interaction between the protein FOXO4 and the tumor-suppressor protein p53 inside senescent cells, freeing p53 to trigger the cell’s programmed death pathway, while reportedly leaving healthy cells unaffected.

What dosage has been studied in humans?

None. No established or reliably sourced dosing information was identified because FOXO4-DRI has not undergone a registered human clinical trial.

What dosage information circulates online?

Peptide-vendor and dosing-guide websites describe self-injected total amounts of roughly 1 to 10 milligrams over short cycling schedules, loosely based on the mouse dosing from the original 2017 study, but this conversion is not supported by any published human data and its origin could not be verified.

Has FOXO4-DRI been studied in humans?

Not in any registered clinical trial identified for this review. All published evidence is from cell culture and mouse studies.

What is a “senolytic”?

A senolytic is any substance designed to selectively clear senescent cells, aging cells that have stopped dividing but resist dying and release inflammatory signals. FOXO4-DRI is one experimental senolytic peptide; dasatinib plus quercetin is a differently-mechanism senolytic drug combination that has reached early human trials.

Is FOXO4-DRI approved for any medical use?

No. It has no approved indication anywhere and remains a research compound.

What remains unknown?

Whether FOXO4-DRI produces senolytic effects or any clinical benefit in humans, what a safe or effective human dose would be, and its long-term safety are all unknown, since it has not been tested in people.

Bottom line

FOXO4-DRI is a scientifically interesting proof-of-concept senolytic peptide with a clear, published mechanism and striking results in mouse aging studies. None of that has been confirmed in humans: there is no registered human trial, no established human dose, and no human safety data. Amounts circulating on peptide-vendor and longevity-community sites are extrapolated from mouse dosing and cannot be verified against any human study. It should be understood as an early-stage research compound, not a validated anti-aging therapeutic.

Related entries: PNC-27, a p53-derived peptide studied in cancer cell research.